Eurand’s AdvaTab Cetirizine Successfully Meets Major Development Milestone

Posted by Administrator on April 12th, 2006 — in Zyrtec Top News

Eurand, a specialty pharmaceutical company, today reported the achievement of a major milestone in the development program for its AdvaTab(R) formulation of cetirizine, a leading prescription antihistamine sold in the United States and other markets as Zyrtec(R). AdvaTab Cetirizine is a taste-masked, stabilized formulation that utilizes Eurand’s proprietary Microcaps tastemasking and AdvaTab orally disintegrating tablet […]

No Comments »

UCB confirms good performance of Zyrtec in US and Xyzal

Posted by Administrator on April 12th, 2006 — in Zyrtec Top News

Following Pfizer’s quarterly earnings release, UCB confirms that Zyrtec continues to strengthen its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US in-market sales of Zyrtec have reached $1,035 million during the past 9 months ending September 30th, 2005 showing a 10% increase against the same […]

No Comments »